Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DP8AS7
|
|||
| Drug Name |
GSK3511294
|
|||
| Synonyms |
depemokimab
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 3 | [1] | |
| chronic rhinosinusitis with nasal polyps [ICD-11: CA0A] | Phase 3 | [2] | ||
| Eosinophilic granulomatosis with polyangiitis [ICD-11: 4A44.A2; ICD-10: M30.1] | Phase 3 | [3] | ||
| Hypereosinophilic syndrome [ICD-11: 2A20.3; ICD-10: D47.5] | Phase 3 | [4] | ||
| Company |
GlaxoSmithKline
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05243680) A Multi-centre, Single Arm, Open-label Extension Study to Evaluate the Long-term Safety of GSK3511294 (Depemokimab) in Adult and Adolescent Participants With Severe Asthma With an Eosinophilic Phenotype From Studies 206713 or 213744. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT05281523) A Randomised, Double-blind, Parallel Group Phase III Study to Assess the Efficacy and Safety of 100 mg SC Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - ANCHOR-2 (depemokimAb iN CHrOnic Rhinosinusitis). U.S.National Institutes of Health. | |||
| REF 3 | ClinicalTrials.gov (NCT05263934) A 52-week, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-centre, Non-inferiority Study to Investigate the Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Receiving Standard of Care (SoC) Therapy. U.S.National Institutes of Health. | |||
| REF 4 | ClinicalTrials.gov (NCT05334368) A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES). U.S.National Institutes of Health. | |||
| REF 5 | A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. Br J Clin Pharmacol. 2022 Feb;88(2):702-712. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.